146 related articles for article (PubMed ID: 16314943)
1. Immunotoxin pharmacokinetics: a comparison of the anti-glioblastoma bi-specific fusion protein (DTAT13) to DTAT and DTIL13.
Rustamzadeh E; Vallera DA; Todhunter DA; Low WC; Panoskaltsis-Mortari A; Hall WA
J Neurooncol; 2006 May; 77(3):257-66. PubMed ID: 16314943
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of antiangiogenic targeted toxins against glioblastoma multiforme.
Hall WA; Vallera DA
Neurosurg Focus; 2006 Apr; 20(4):E23. PubMed ID: 16709029
[TBL] [Abstract][Full Text] [Related]
3. A bispecific immunotoxin (DTAT13) targeting human IL-13 receptor (IL-13R) and urokinase-type plasminogen activator receptor (uPAR) in a mouse xenograft model.
Todhunter DA; Hall WA; Rustamzadeh E; Shu Y; Doumbia SO; Vallera DA
Protein Eng Des Sel; 2004 Feb; 17(2):157-64. PubMed ID: 15047912
[TBL] [Abstract][Full Text] [Related]
4. Targeting the over-expressed urokinase-type plasminogen activator receptor on glioblastoma multiforme.
Rustamzadeh E; Li C; Doumbia S; Hall WA; Vallera DA
J Neurooncol; 2003 Oct; 65(1):63-75. PubMed ID: 14649886
[TBL] [Abstract][Full Text] [Related]
5. Targeting urokinase-type plasminogen activator receptor on human glioblastoma tumors with diphtheria toxin fusion protein DTAT.
Vallera DA; Li C; Jin N; Panoskaltsis-Mortari A; Hall WA
J Natl Cancer Inst; 2002 Apr; 94(8):597-606. PubMed ID: 11959893
[TBL] [Abstract][Full Text] [Related]
6. Intracranial therapy of glioblastoma with the fusion protein DTIL13 in immunodeficient mice.
Rustamzadeh E; Hall WA; Todhunter DA; Low WC; Liu H; Panoskaltsis-Mortari A; Vallera DA
Int J Cancer; 2006 May; 118(10):2594-601. PubMed ID: 16358262
[TBL] [Abstract][Full Text] [Related]
7. Intracranial therapy of glioblastoma with the fusion protein DTAT in immunodeficient mice.
Rustamzadeh E; Hall WA; Todhunter DA; Vallera VD; Low WC; Liu H; Panoskaltsis-Mortari A; Vallera DA
Int J Cancer; 2007 Jan; 120(2):411-9. PubMed ID: 17075792
[TBL] [Abstract][Full Text] [Related]
8. Malignant progenitors from patients with CD87+ acute myelogenous leukemia are sensitive to a diphtheria toxin-urokinase fusion protein.
Frankel AE; Beran M; Hogge DE; Powell BL; Thorburn A; Chen YQ; Vallera DA
Exp Hematol; 2002 Nov; 30(11):1316-23. PubMed ID: 12423685
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of antiangiogenic targeted immunotoxin DTAT and DTATEGF against glioblastoma multiforme.
Huang J; Yuan D; Liu D; Li J; Li Y; A Hall W; Li B
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2014 Jan; 39(1):1-5. PubMed ID: 24473378
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of a bispecific biological drug designed to simultaneously target glioblastoma and its neovasculature in the brain.
Oh S; Tsai AK; Ohlfest JR; Panoskaltsis-Mortari A; Vallera DA
J Neurosurg; 2011 Jun; 114(6):1662-71. PubMed ID: 21294620
[TBL] [Abstract][Full Text] [Related]
11. Targeting glioblastoma multiforme with an IL-13/diphtheria toxin fusion protein in vitro and in vivo in nude mice.
Li C; Hall WA; Jin N; Todhunter DA; Panoskaltsis-Mortari A; Vallera DA
Protein Eng; 2002 May; 15(5):419-27. PubMed ID: 12034862
[TBL] [Abstract][Full Text] [Related]
12. The diphtheria toxin/urokinase fusion protein (DTAT) is selectively toxic to CD87 expressing leukemic cells.
Ramage JG; Vallera DA; Black JH; Aplan PD; Kees UR; Frankel AE
Leuk Res; 2003 Jan; 27(1):79-84. PubMed ID: 12479856
[TBL] [Abstract][Full Text] [Related]
13. Anti-glioblastoma effect of a recombinant bispecific cytotoxin cotargeting human IL-13 and EGF receptors in a mouse xenograft model.
Stish BJ; Oh S; Vallera DA
J Neurooncol; 2008 Mar; 87(1):51-61. PubMed ID: 18084721
[TBL] [Abstract][Full Text] [Related]
14. Recombinant immunotoxins directed against the c-erb-2/HER2/neu oncogene product: in vitro cytotoxicity, pharmacokinetics, and in vivo efficacy studies in xenograft models.
Rosenblum MG; Shawver LK; Marks JW; Brink J; Cheung L; Langton-Webster B
Clin Cancer Res; 1999 Apr; 5(4):865-74. PubMed ID: 10213223
[TBL] [Abstract][Full Text] [Related]
15. Modulation of invasive properties of human glioblastoma cells stably expressing amino-terminal fragment of urokinase-type plasminogen activator.
Mohanam S; Chandrasekar N; Yanamandra N; Khawar S; Mirza F; Dinh DH; Olivero WC; Rao JS
Oncogene; 2002 Nov; 21(51):7824-30. PubMed ID: 12420219
[TBL] [Abstract][Full Text] [Related]
16. Intracranial elimination of human glioblastoma brain tumors in nude rats using the bispecific ligand-directed toxin, DTEGF13 and convection enhanced delivery.
Oh S; Ohlfest JR; Todhunter DA; Vallera VD; Hall WA; Chen H; Vallera DA
J Neurooncol; 2009 Dec; 95(3):331-342. PubMed ID: 19517064
[TBL] [Abstract][Full Text] [Related]
17. Increasing anticarcinoma activity of an anti-erbB2 recombinant immunotoxin by the addition of an anti-EpCAM sFv.
Stish BJ; Chen H; Shu Y; Panoskaltsis-Mortari A; Vallera DA
Clin Cancer Res; 2007 May; 13(10):3058-67. PubMed ID: 17505009
[TBL] [Abstract][Full Text] [Related]
18. Intracerebral infusion of the bispecific targeted toxin DTATEGF in a mouse xenograft model of a human metastatic non-small cell lung cancer.
Huang J; Li YM; Massague J; Sicheneder A; Vallera DA; Hall WA
J Neurooncol; 2012 Sep; 109(2):229-38. PubMed ID: 22696210
[TBL] [Abstract][Full Text] [Related]
19. Construction and preliminary investigation of a plasmid containing a novel immunotoxin DT390-IL-18 gene for the prevention of murine experimental autoimmune encephalomyelitis.
Jia J; Li H; Tai S; Lv M; Liao M; Yang Z; Zhang B; Zhou B; Zhang G; Zhang L
DNA Cell Biol; 2008 May; 27(5):279-85. PubMed ID: 18346003
[TBL] [Abstract][Full Text] [Related]
20. In vivo biotherapy of HL-60 myeloid leukemia with a genetically engineered recombinant fusion toxin directed against the human granulocyte macrophage colony-stimulating factor receptor.
Perentesis JP; Gunther R; Waurzyniak B; Yanishevski Y; Myers DE; Ek O; Messinger Y; Shao Y; Chelstrom LM; Schneider E; Evans WE; Uckun FM
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2217-27. PubMed ID: 9815618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
